Roles of HIF and 2-Oxoglutarate-Dependent Dioxygenases in Controlling Gene Expression in Hypoxia by Frost, Julianty et al.
cancers
Review
Roles of HIF and 2-Oxoglutarate-Dependent Dioxygenases in
Controlling Gene Expression in Hypoxia
Julianty Frost 1, Mark Frost 1 , Michael Batie 1 , Hao Jiang 2 and Sonia Rocha 1,*


Citation: Frost, J.; Frost, M.; Batie,
M.; Jiang, H.; Rocha, S. Roles of HIF
and 2-Oxoglutarate-Dependent
Dioxygenases in Controlling Gene
Expression in Hypoxia. Cancers 2021,
13, 350. https://doi.org/10.3390/
cancers13020350
Received: 24 November 2020
Accepted: 15 January 2021
Published: 19 January 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Department of Molecular Physiology and Cell Signalling, Institute of Systems, Molecular and Integrative
Biology, University of Liverpool, Liverpool L69 7ZB, UK; Julianty.Frost@liverpool.ac.uk (J.F.);
Mark.Frost@liverpool.ac.uk (M.F.); M.Batie@liverpool.ac.uk (M.B.)
2 Centre for Gene Regulation and Expression, School of Life Sciences, University of Dundee,
Dundee DD1 5EH, UK; h.y.jiang@dundee.ac.uk
* Correspondence: srocha@liverpool.ac.uk; Tel.: +44-(0)151-794-9084
Simple Summary: Hypoxia—reduction in oxygen availability—plays key roles in both physiolog-
ical and pathological processes. Given the importance of oxygen for cell and organism viability,
mechanisms to sense and respond to hypoxia are in place. A variety of enzymes utilise molecular
oxygen, but of particular importance to oxygen sensing are the 2-oxoglutarate (2-OG) dependent
dioxygenases (2-OGDs). Of these, Prolyl-hydroxylases have long been recognised to control the
levels and function of Hypoxia Inducible Factor (HIF), a master transcriptional regulator in hypoxia,
via their hydroxylase activity. However, recent studies are revealing that such dioxygenases are
involved in almost all aspects of gene regulation, including chromatin organisation, transcription
and translation.
Abstract: Hypoxia—reduction in oxygen availability—plays key roles in both physiological and
pathological processes. Given the importance of oxygen for cell and organism viability, mechanisms
to sense and respond to hypoxia are in place. A variety of enzymes utilise molecular oxygen, but of
particular importance to oxygen sensing are the 2-oxoglutarate (2-OG) dependent dioxygenases
(2-OGDs). Of these, Prolyl-hydroxylases have long been recognised to control the levels and function
of Hypoxia Inducible Factor (HIF), a master transcriptional regulator in hypoxia, via their hydroxylase
activity. However, recent studies are revealing that dioxygenases are involved in almost all aspects
of gene regulation, including chromatin organisation, transcription and translation. We highlight
the relevance of HIF and 2-OGDs in the control of gene expression in response to hypoxia and their
relevance to human biology and health.
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1. Introduction
The importance of oxygen for energy production in multicellular organisms has been
appreciated since the identification of the mechanism of oxidative phosphorylation located
in the mitochondria. Reduction in oxygen availability, or hypoxia, is therefore either a
danger signal or a cue for physiological processes such as development. Every cell has
a different threshold for mounting a hypoxia response, although the exact mechanisms
dictating this threshold are currently not well understood. Given the importance of oxygen,
cells have evolved sophisticated mechanisms to sense and respond to hypoxia, in order
to minimise damage, preserve energy and, when possible, adapt to the new oxygen
supply normality.
The main transcription factor activated under low oxygen conditions, called Hypoxia
Inducible Factor (HIF), was identified in 1992 [1]. HIF is composed of a heterodimer of HIF-
α (of which there are three isoforms encoded by three different genes, HIF-1α, HIF-2α and
HIF3-α) and HIF-1β [2]. HIF3-α, unlike the other HIF-αs, lacks a transactivation domain,
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and is thought to act either as a dominant-negative or transcription-independent regulator
of the hypoxic response [3]. HIFs control many genes, most of which are crucial for cell sur-
vival and adaptation to low oxygen conditions [2]. Under pathological conditions, such as
cancer and altitude sickness, induction of some of these genes by the HIF transcription
factors has been linked to disease progression and treatment resistance [4]. In addition,
HIF can also be induced by non-oxygen dependent mechanisms, such as inflammation [5].
This is particularly relevant for human cancers, where hypoxia and inflammation often
co-occur [6].
The detailed mechanism leading to the activation of HIF was unravelled in 2001 [7,8],
building on accumulated knowledge of the role of Von Hippel–Lindau Tumor Suppressor
(VHL) in this process [9,10]. HIF-α, under normal oxygen conditions, is continually
transcribed and translated, but rapidly degraded by the ubiquitin dependent proteasomal
system (Figure 1). Ubiquitination is promoted by the E3-ligase composed of VHL, Ring-Box
1 (RBX1), Cullin 2 (CUL2) and Elongin B/C (ELOCB/C) [4]. VHL affinity toward HIF-α
is dramatically increased by the presence of a specific post-translational modification,
more precisely two separate proline hydroxylation events (Figure 1), mediated by Prolyl-
Hydroxylases (PHDs). PHDs are part of the 2-oxoglutarate (2-OG) dependent dioxygenase
(2-OGD) superfamily of enzymes, requiring oxygen, iron (II) and 2-OG for activity [11].
Mammals possess three PHDs, PHD2 (gene name EGLN1), PHD3 (gene name EGLN3) and
PHD1 (gene name EGLN2) [7].




Figure 1. Regulation of HIF levels and activity in normoxia and hypoxia. Under normal oxygen 
conditions, (A), normoxia, HIF-α is constantly hydroxylated by PHDs and FIH. PHD-mediated 
hydroxylation increases binding affinity with the tumour suppressor VHL, which promotes ubiq-
uitination and degradation by the proteosome. As oxygen levels decrease, in mild hypoxia (15–1% 
O2) (B), PHDs are inhibited, HIF-α is stabilised, though still hydroxylated by FIH, binds to HIF-1β 
and is able to induce transcription of certain target genes. With further reduction in oxygen levels, 
in severe hypoxia (<1% O2) (C), FIH is also inhibited and HIF is able to become fully active by the 
recruitment of co-activators such as p300. 
Table 1. 2-OGDs with reported affinities for oxygen from in vitro assays. The KM values for oxygen have been deter-
mined via a range of in vitro experiments. The KM obtained is affected by substrate, conditions, and technique, and there-
fore provides only a possible indication of oxygen sensing capability. We have assessed, from the reported KMs and cellular 
data, whether these 2-OGDs might act as oxygen sensors. * Median KM from multiple studies (individual values listed in 
Supplementary Table S1). 









PHD1 230 [17] Y Multiple Y 
PHD2 240 * [12,17–19] Y Multiple  
PHD3 230 [17] Y Multiple  
4-PHα1 40 [17]  Collagen  
PAHX 93 ± 43 [12,17] Y Isovaleryl CoA  
CDO1 76 ± 17 [12] N Taurine  
FIH 110 ± 30 * [12,20,21] Y/N Multiple Y 
Hydroxylases (known as 
DNA demethylases) 
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TET2 30 ± 3 [22] N DNA Y 
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Figure 1. Regulation of HIF levels and activity in normoxia and hypoxia. Under normal oxygen conditions, (A), normoxia,
HIF-α is constantly hydroxylated by PHDs and FIH. PHD-mediated hydroxylation increases binding affinity with the
tumour suppressor VHL, which promotes ubiquitination and degradation by the proteosome. As oxygen levels decrease,
in mild hypoxia (15–1% O2) (B), PHDs are inhibited, HIF-α is stabilised, though still hydroxylate by FIH, binds to HIF-1β
and is able to i uce transcription of ertain targ t genes. With further reduction in oxygen levels, in evere hypoxia
(<1% O2) (C), FIH is also inhibited and HIF is able to become fully active by the recruit ent of co-activators such as p300.
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Biochemical characterisation revealed that PHDs have low affinity for molecular oxy-
gen. Low affinity for molecular oxygen signifies that when oxygen availability is reduced,
these enzymes are quickly inhibited, leading to HIF stabilisation and activation of target
genes. PHD inhibition in hypoxia has resulted in them being termed molecular oxygen
sensors in the cell [12]. Additionally, many more 2-OGDs have been identified, most of
which act independently of HIF but play a role in coordinating the cellular response to
hypoxia. These include Factor Inhibiting HIF1 (FIH), Jumonji C (JmjC)-domain containing
demethylases (JmjC demethylases) (which demethylate both histones and non-histone
proteins), Ten-Eleven Translocation (TET) enzymes (mediators of DNA-demethylation),
and RNA-demethylases (reported in vitro for 2-ODGs are shown is Table 1 and Supplemen-
tary Table S1). Given the function of some of these enzymes, it is conceivable that hypoxia
could influence all aspects of gene expression, from chromatin structure and epigenetics to
RNA biology, translation and protein turnover (Figure 2). This perfectly equips the cell
when faced with hypoxia. Under such conditions, the cell must make a coordinated effort
to allow for restoration of oxygen homeostasis, while reducing energy expenditure if it is
to survive.
















KDM4E 197 ± 16 [24] Y H3K9me3Histone H3 Y 
KDM5A 90 ± 30 [25] Y H3K4me2/me3H stone H3 Y 
KDM5B 40 ± 10 [25] N H3K4me2/m 3Histone H3 Y 
KDM5C 35 ± 10 [25] N H3K4me2/ e3Histone H3 Y 
KDM5D 25 ± 5 [25] N H3K4me2/me3Histone H3 Y 
KDM6A 180 ± 40 [25] Y H3K27me2/me3Histone H3 Y 
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Figure 2. Control of gene expression by 2-ODGs in hypoxia. Hypoxia via the regulation of 2-
OGDs has the potential of controlling all aspects of gene expression and protein function. Action 
of JmjC-histone demethylases and TETs (mediators of DNA demethylation) will impact on chro-
matin and DNA regulation. RNA demethylases, and several hydroxylases acts on mRNA pro-
cessing, and fate. Hydroxylases also control rates of translation and ribosome activity, while JmjC-
demethylases and hydroxylases can control protein function directly or indirectly by controlling 
other PTMs. 
i t l i xia. oxia via the regulation of 2-OGDs
has the potential of controlli g all aspects of gene expression and protein function. Action of JmjC-
histone demethylases and TETs (mediators of DNA demethylation) will impact on chromatin and
DNA regulation. RNA demethylases, and several hydroxylases acts on mRNA processing, and fate.
Hydroxylases also control rates of translation and ribosome activity, while JmjC-demethylases and
hydroxylases can control protein function directly or indirectly by controlling other PTMs.
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Genetic models in several model organisms have helped identify the key roles of
HIFs as well as 2-OGDs in development and disease (Table 2; Supplementary Table S2).
Furthermore, genome wide mapping techniques such as chromatin immunoprecipitation
followed by sequencing (ChIP-seq), RNA sequencing (RNA-seq), and Chromatin capture
have more recently been used to better understand how cells responds to changes in
oxygen, but also in response to 2-OGD inhibition ([13,14] and reviewed in [15,16]).
Table 1. 2-OGDs with reported affinities for oxygen from in vitro assays. The KM values for oxygen have been determined
via a range of in vitro experiments. The KM obtained is affected by substrate, conditions, and technique, and therefore
provides only a possible indication of oxygen sensing capability. We have assessed, from the reported KMs and cellular
data, whether these 2-OGDs might act as oxygen sensors. * Median KM from multiple studies (individual values listed in
Supplementary Table S1).
2-OGD Type Enzyme O2 KM (µM)
Potential O2
Sensor (Yes/No) Substrate
Effect on Gene Expression
in Hypoxia
Hydroxylases
PHD1 230 [17] Y Multiple Y
PHD2 240 * [12,17–19] Y Multiple
PHD3 230 [17] Y Multiple
4-PHα1 40 [17] Collagen
PAHX 93 ± 43 [12,17] Y Isovaleryl CoA
CDO1 76 ± 17 [12] N Taurine
FIH 110 ± 30 * [12,20,21] Y/N Multiple Y
Hydroxylases (known as
DNA demethylases)
TET1 30 ± 10 [22] N DNA Y
TET2 30 ± 3 [22] N DNA Y
JmjC demethylases
KDM4A 60 ± 20 * [23–25] Y H3K9me2/me3, H3K36me2,H1.4K26me2/me3 Y
KDM4B 150 ± 40 [25] Y H3K9me2/me3, H3K36me2,H1.4K26me2/me3 Y
KDM4C 158 ± 13 [24] Y H3K9me2/me3, H3K36me2,H1.4K26me2/me3Histone H3 Y
KDM4E 197 ± 16 [24] Y H3K9me3Histone H3 Y
KDM5A 90 ± 30 [25] Y H3K4me2/me3Histone H3 Y
KDM5B 40 ± 10 [25] N H3K4me2/me3Histone H3 Y
KDM5C 35 ± 10 [25] N H3K4me2/me3Histone H3 Y
KDM5D 25 ± 5 [25] N H3K4me2/me3Histone H3 Y
KDM6A 180 ± 40 [25] Y H3K27me2/me3Histone H3 Y




ADO >500 [26] Y RGS4 and RGS5
Table 2. Available mice and human mutations phenotypes for HIF and dioxygenases.
Gene (Mouse/Human) Homozygote Phenotype in Mouse Human Phenotype
HIFs
Hif1a/HIF1A (HIF-1α) Embryonic lethal with cardiovascular malformations, cephalicvascularisation and neural tube defects [27–29]
Schizophrenia [30]. Maximal oxygen consumption [31]. Renal cell
carcinoma [32].
Epas1/EPAS1 (HIF-2α)
Embryonic lethal with bradycardia due to defective catecholamine
homeostasis [33], vascular remodelling defects [34], cardiac failure
and neonatal lethal with respiratory failure [35].
Congenital heart disorder [36]. Autism spectrum disorder [37].
Pheochromocytoma/paraganglioma-polycythaemia [38–44]
/somatostatinoma [45]. Erythrocytosis and polycythaemia with
paraganglioma [40–42]. Erythrocytosis [46–51]. Pulmonary arterial
hypertension [52].
Hif3a/HIF3A (HIF-3α)
Mice deficient of an alternative spliced protein of HIF-3α, NEPAS,
are viable and develop enlarged right ventricular owing to
impaired pulmonary remodelling [53].
NR
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Table 2. Cont.
Gene (Mouse/Human) Homozygote Phenotype in Mouse Human Phenotype
2-OGDs—hydroxylases
Egln2/EGLN2 (PHD1) Viable [54].
Increased risk of hepatocellular carcinoma [55], lung cancer [56,57],
gastric cancer [58], colorectal cancer [59].
Pheochromocytoma/paraganglioma-polycythemia [60].
Egln1/EGLN1 (PHD2) Embryonic lethal with severe cardiac and placental defects [54].
High-altitude adaptation [45]. Erythrocytosis [61–71].
Pheochromocytoma/paraganglioma-polycythemia [60].
Pheochromocytoma [39]. Cardiopulmonary [72].
Egln3/EGLN3 (PHD3) Viable [54] with developmental defect of sympathoadrenalsystem [73]. NR
P4ha1/P4HA1 Embryonic lethal with delayed development and defectivecollagen IV assembly, resulting in base membrane rupture [74]. Congenital-onset disorder of connective tissue [75].
P4ha2/P4HA2 Viable and fertile with no obvious phenotypic abnormalities [76]. High myopia [77].
Phyh/PHYH (PAHX) Viable without distinct developmental abnormalities [78]. Refsum disease [79–85]. Nonsyndromic cleft lip and palate [86].
Hif1an/HIF1AN (FIH) Abnormal energy metabolism with reduced body weight, elevatedmetabolic rate and hyperventilation [87]. Colorectal cancer [88].
2-OGDs—hydroxylases (mediators of DNA demethylation)
Tet1/TET1
Knockout of TET1 via 5’ coding sequence results in partial
embryonic lethality in mice [89–91], with surviving female mice
displaying decreased fertility and reduced ovary size due to
meiotic abnormality [89,90]. Whereas, mice with knockout via
deletion of the catalytic domain of TET1 are viable and
fertile [91–93], with slightly reduced body size [92], as well as
impaired spatial learning and short-term memory [94].
NR
Tet2/TET2 Disordered hematopoiesis and eventually develop myeloidmalignancies [95–97], and T- and B-cell malignancies [96].
Myelodysplastic/myeloproliferative disease [98]. Prostate
cancer [99]. Myeloproliferative neoplasms [100].
Tet3/TET3 Neonatal lethality [90,101].
Intellectual disability, developmental delay, autistic traits,
hypotonia, growth abnormalities, facial dysmorphism and
movement disorders [102].
2-OGDs—hydroxylases (RNA demethylases)
Fto/FTO Abnormal brain and cardiac development [103].
Developmental delay and dysmorphic facial features [104].
Growth retardation and multiple malformations [103].
Developmental delay and growth retardation [105]. Growth
retardation and multiple malformations [106]. Obesity [107,108].
Type II diabetes [109]. Metabolic syndrome including obesity,
hypertension, dyslipidemia, and defective glucose tolerance [110].
2-ODGs—JmjC demethylases and hydroxylases
Jmjd4/JMJD4 Viable and fertile with normal physiology [111]. NR
Jmjd6/JMJD6
Perinatal lethal with growth retardation and exhibit severe tissue
and organ differentiation defects, including brain, lung, liver,
kidney, intestine, heart and thymus development at different
stages of embryogenesis [112–115].
NR
Kdm2a/KDM2A Embryonic lethal with severe growth retardation and defectiveneural tube closure [116]. NR
Kdm2b/KDM2B
KDM2B-1-deletion mice display moderate penetrance of neural
tube defects, leading to exencephaly and death at birth [117].
Whereas, mice deficient of both KDM2B-1 and KDM2B-2 isoforms
are embryonic lethal with fully penetrant developmental defects,
including abnormal somitogenesis, reduced size, defective neural
tube and heart [118–120]; especially a more severe developmental
defect in female embryos [119]. Furthermore, KDM2B-2-deleted
mice display similar developmental abnormalities with increased
lethality, particularly in females [119].
NR
Kdm3a/KDM3A
Develop obesity, abnormal fat metabolism [121,122], reduced
energy expenditure, and display metabolic syndrome, including,
high plasma cholesterol, insulin, triglyceride, and leptin
levels [122]. Male infertility, smaller testes and severe
oligozoospermia [123]. Retarded mammary gland ductal growth
in female knockout mice [124].
Male infertility [125].
Kdm3b/KDM3B
Postnatal growth restriction and female mice were infertile due to
decreased ovulation, prolonged estrous cycles, reduced
fertilisation and uterine decidual response [126]. Male knockout
mice have impaired reproductive function, sperm development
and maturation [126]. Knockout mice exhibit myelodysplastic
syndrome and defective hematopoiesis including leukocytosis,
moderate anemia, and granulocytosis [127].
Schizophrenia [128]. Intellectual disability [129]. Wilms tumour
and hyperpigmentation [130]. Hepatoblastoma, autism,
intellectual disability, and abnormal pigmentation [130]. Acute
myeloid leukemia, mild intellectual disability, congenital
hypothyroidism and congenital hip dysplasia [130]. Hodgkin
lymphoma, feeding difficulties, intellectual disability, umbilical
and inguinal hernia [131]. Intellectual disability, facial
dysmorphism and short stature [131].
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Table 2. Cont.
Gene (Mouse/Human) Homozygote Phenotype in Mouse Human Phenotype
Jmjd1c/JMJD1C Males gradually develop infertility with decreasing testes size dueto progressive loss of germ cells [127].
Congenital heart disease in patients with 22q11.2 deletion
syndrome [132]. Rett syndrome [133,134]. Autism spectrum
disorder [133]. Intellectual disability [133]. Intracranial germ cell
tumour [58].
Kdm4a/KDM4A Viable [135]. NR
Kdm4b/KDM4B
Viable [136]. Viable with lower birth rate. Early weaning results in
death. Susceptible to obesity with impaired energy expenditure,
adaptive thermogenesis and adipose tissue lipolysis [137].
NR
Kdm4c/KDM4C Viable and fertile [138]. However, another reported that it leads toembryonic lethality [139]. Upper aerodigestive tract cancer [140]. Age at menarche [141].
Kdm4d/KDM4B Viable and fertile without gross abnormalities [142]. NR
Kdm5a/KDM5A Viable [143,144]. Mice displayed mild behavioural andhaematological abnormalities [143]. Intellectual disability [145]. Congenital heart disease [146].
Kdm5b/KDM5B
Embryonic lethal [147,148]. Neonatal lethal due to failure to
establish respiratory function, defective neural system and
homeotic skeletal transformations [149].
Intellectual disability, dyslexia, global developmental delay, facial
dysmorphism, aggressive behaviour, hypospadias [150].
Kdm5c/KDM5C
Hemizygous KDM5C null male mice are embryonic lethal due to
defective neurulation and cardiogenesis [151]. Male hemizygous
knockout mice (Kdm5c−/y) Viable with adaptive and cognitive
abnormalities, including increased aggression, impaired social
behaviour, limited learning, fear memory deficits, defective
dendritic spines [152,153] and significant reduced body
weight [153].
X-linked intellectual disability [154–166]. Autism spectrum
disorder [167].
Kdm5d/KDM5D
A large scale screening using CRISPR/Cas9-mediated genome
editing reveals normal reproductive system in hemizygous
KDM5D-knockout male mice [168].
NR
Kdm6a/KDM6A
Embryonic lethal with cardiac development defects and neural
tube closure. While female knockout mice died mid-gestational,
some hemizygous KDM6A-null male mice survive into
adulthood [151,169–172] and are fertile [171,172], with reduced
lifespan and smaller size [171]. Female embryonic lethal,
abnormal/truncated posterior bodies, anaemic (hematopoiesis),
severe heart development defect and neural tube closure. Male
died around birth due to neural tube closure defect and inability to
breath [173].
Kabuki syndrome [174–183]. Biliary atresia with Kabuki
syndrome-like features [184]. Renal cancer [185].
Kdm6b/KDM6B
Embryonic [186] and perinatal lethal with respiratory
failure [187–189], detail reviewed here [190]. Reduced proliferation
and hypertrophy of chondrocytes, as well as delayed
endochondral ossification in mice [191]. Delayed osteoblast
differentiation and bone ossification [192].
Intellectual disability [145]. Intellectual disability, brachydactyly
and dysmorphism [193].
Uty/UTY Hemizygous male mice are viable [169]. NR
Kdm7a/KDM7A
A large-scale genome-wide tissue phenotype screen revealed that
abnormal hair follicles, sebaceous gland, tail and hair follicle bulge
morphology in KDM7A knockout mice [194].
Phf8/PHF8 Impaired learning and memory, hippocampal long-termpotentiation [195].
X-linked mental retardation with cleft lip/palate [196–198].
Autism and Asperger syndrome [199]. Autism spectrum disorder,
intellectual disability, cleft palate and Aarskog syndrome [200].
Intellectual disability [159].
Kdm8/KDM8 Embryonic lethal with delayed development in multipleorgans [201] and growth retardation [202]. NR
In this review, we highlight the importance of oxygen sensing in coordinating an effi-
cient response to hypoxia. We discuss the relevance of HIF transcription factors, and roles
of 2-OGDs in controlling almost all aspects of gene expression from chromatin structure,
to transcription, translation and post-translational modifications.
2. Effects of Hypoxia on Gene Transcription
It is now appreciated that the cellular and organism response to hypoxia involves
profound changes to gene expression, with vast changes in gene transcription being
detected in all systems studied.
Hypoxia-Induced Changes to Transcription Are Largely Mediated by HIF
As mentioned earlier HIFs are the master regulators of gene transcriptional changes in
hypoxia and this has been extensively reviewed previously [2,11,203]. The discovery of hy-
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poxia responsive genes and HIF targets has been driven greatly by transcript profiling and
genome occupancy technologies, including microarrays, RNA-seq and ChIP-seq (reviewed
in [15,16,204]). These analyses of publicly available transcriptional datasets [205,206] have
shed light on cell type differences in hypoxia responsive genes and HIF targets on a genome
wide scale, as well as identifying hypoxic signatures conserved across multiple cell types.
Why different cell types have different transcriptional responses to hypoxia and HIF target
genes is an important question for the field, with chromatin structure organisation thought
to be a major factor in conferring specificity. Further to HIF isoform expression and activity,
evidence points towards pre-established chromatin accessibility and local chromatin envi-
ronment, including RNA pol II availability, pre-existing promoter enhancer interactions at
HREs, and HRE DNA methylation status, as cell-type specificity determinants of hypoxia
transcriptional responses (reviewed in [15,16,204,207]).
Whilst most HIF binding sites are at proximal promoters, binding to distal inter-
genic regions also occurs and HIF can regulate transcription of long genomic intervals,
interacting at promoter-enhancer loops [208–210]. Although there is no doubt HIF is the
main transcription factor controlling hypoxia-induced transcriptional changes, there is
involvement of other transcription factors, including Nuclear Factor-κB (NF-κB), Tumor
Protein p53 (p53), MYC Proto-Oncogene (MYC) and Activator Protein 1 (AP1), which func-
tion in the regulation of the hypoxia response via HIF-dependent and independent path-
ways (reviewed in [211]). In addition, HIF mostly acts as an activator of transcription,
and thus most of the observed hypoxia-induced gene silencing is either independent of
HIF, or via indirect mechanisms, including through the actions of chromatin remodeller
complexes, co-repressor complexes or induction of other transcription factors (reviewed
in [212]). HIF induced genes are involved in a variety of different pathways involved
in restoration of oxygen homeostasis [2,11,203]. Importantly, many 2-OGDs, including
PHD2 [213] and PHD3 [214], several JmjC demethylases (reviewed in [215]), and TET1 [216]
and TET3 [216,217], are HIF target genes that have been shown to be transcriptionally
upregulated in response to hypoxia.
Although we now have access to a vast number of transcriptomic studies of cells in hy-
poxia, very few studies have investigated the proteomic changes under such an important
stress, using techniques ranging from the “old-fashioned” two-dimensional electrophoresis
(2-DE) coupled with MALDI-TOF-TOF-MS [218–220], to the more accurate and robust
quantitative multiplexed proteomics workflow [221–224], which usually combines iso-
baric labelling, two-dimensional liquid chromatography (2D-LC) and high resolution MS.
The few studies available have shown that hypoxia exposure of different cells and tissues
possesses broad effects at the whole proteome level, including changes to the protein expres-
sion of annexin family [218], glycolytic and antioxidant enzymes [219,220], transcription
factors [225], heat shock proteins, S100 family proteins [221], and also other proteins in-
volved in the TCA-cycle [226], metabolism [227] and immune response [222]. A proteomic
study has revealed novel non-HIF hypoxia regulators, including the chromatin organizer
protein Heterochromatin Protein 1 Binding Protein 3 (HP1BP3), which mediates chromatin
condensation [223]. The use of multi-omics techniques (transcriptomics, proteomics and
metabolomics) and analysis using integrated bioinformatics identified consistent changes
to proteins and metabolites in heart tissues under antenatal hypoxia. These proteins and
metabolites are involved in energy metabolism, oxidative stress and inflammation-related
pathways, required for the reprogramming of the mitochondrion [224].
3. Chromatin Regulation in Hypoxia
Central to the hypoxia response is the activation of a dynamic transcriptional pro-
gramme. HIF transcription factors are the primary mediators of hypoxia induced gene
transcriptional changes (reviewed in [11]). Further to HIF stabilisation and activation under
low oxygen tensions, the chromatin landscape also plays a complex role in coordinating
hypoxia inducible changes to gene transcription. Most aspects of chromatin regulation
are altered in response to low oxygen, including histone methylation and acetylation,
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DNA methylation, actions of chromatin remodeller complexes and non coding RNAs,
histone eviction and incorporation of histone variants, and chromatin accessibility (re-
viewed in [15,16,203]). However, this is still a vastly unexplored aspect of the hypoxia
response. As mentioned above, in addition to PHDs, TETs (mediators of DNA demethy-
lation), and JmjC demethylases (histone and non-histone protein demethylases), are also
2-OGDs. Recent studies demonstrate the potential of TETs and JmjC demethylases to func-
tion as molecular oxygen sensors, directly linking oxygen sensing to transcriptional control
via epigenetics in cells. Below we summarise DNA and histone methylation changes in
hypoxia, with a focus on oxygen sensing mechanisms via TETs and JmjC demethylases
(Figure 3).
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3.1. JmjC Demethylases and Chromatin Regulation in Hypoxia
Histone methylation is a recognised mechanism controlling chromatin structure and is
associated with regulation of gene transcription, with some marks clearly leading to open
chromatin, while others are firmly associated with closed conformation [228]. The family
of enzymes predominantly responsible for histone demethylation are JmjC demethylases,
which are part of the JmjC-domain containing group of 2-OGDs that includes demethylases
and hydroxylases (JmjC 2-ODGs)). In vitro studies demonstrate the varied oxygen sensitiv-
ities of these enzymes, some are potentially direct molecular oxygen sensors (Table 1 and
Supplementary Table S1). Oxygen affinities, oxygen availability and protein expression
levels will likely dictate JmjC demethylase activities in hypoxia. Several groups have re-
ported increases in total levels of histone methylation modifications in response to hypoxia
across a range of human and mouse cell types and human tumours using immunoblot-
ting, immunohistochemistry, immunofluorescence and quantitative proteomics ([229], re-
viewed in [16]). ChIP-sequencing approaches have revealed site-specific, hypoxia-induced
changes in Histone (H)3 Lysine (K)4 trimethylation ( e3) [230,231], H3K36me3 [230]
and H3K27me3 [25,231], which correlate with changes in gene expression. There is now
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evidence, through the use of in vitro and in cell histone demethylation assays, in coor-
dination with mutagenesis analysis, gene expression analysis and histone methylation
analysis, that Lysine Demethylase (KDM) 6A (KDM6A) [25] and potentially KDM5A [230],
which demethylate H3K27me3 and H3K4me3 respectively, are inhibited by reduced oxygen
levels in hypoxia. These result in increased histone methylation modifications, which co-
ordinate hypoxia inducible gene transcriptional changes (Figure 3) and hypoxia induced
cellular responses. Specifically, KDM6A inhibition in hypoxia triggers hypermethylation
of H3K27me3 at a subset of hypoxia repressed gene promoters, reducing their expression.
Conversely, potential KDM5A inhibition in hypoxia, triggers H3K4me3 hypermethyla-
tion at a subset of hypoxia inducible gene promoters, this precedes increases in their
expression in hypoxia and is required for their full transcriptional activation in hypoxia.
In cell and in vitro H3K9me3 demethylation assays have also revealed that the demethy-
lase activity of KDM4A is highly sensitive to oxygen concentrations over physiologically
relevant ranges [24]. Although there are a range of reported in vitro oxygen affinities,
(Supplementary Table S1) the data from cells show that KDM4A activity is sensitive to
oxygen levels. There is evidence that reduced histone demethylase activity of KDM4A
in severe hypoxia (<0.5% oxygen), along with KDM4C, triggers increased expression of
a subset of androgen receptor target genes [232]. Thus, KDM4A can also be classed as
an oxygen sensor. Interestingly, KDM4A has been shown to positively regulate HIF-1α
levels via H3K9me3 demethylation at the HIF1A gene locus, this effect is observed in mild
hypoxia (2% oxygen), but impaired at severe hypoxia (<0.1% oxygen) [233]. This may
provide a mechanism of maintaining HIF-1α levels in conditions of mild hypoxia specif-
ically, where there is still residual PHD activity. Future work should investigate if the
oxygen sensitive H3K9me3 demethylase activity of KDM4A is linked to control of gene
expression and chromatin regulation in hypoxia. Importantly, some JmjC demethylases
remain active at low oxygen concentrations and function in hypoxia through their histone
demethylase activity. KDM4C [234] and KDM3A [235,236] display HIF coactivator activity
in hypoxia via demethylation of H3K9 at HIF target gene promoters, facilitating transcrip-
tional activation at these genes. The co-activator role of KDM3A in hypoxia, via retained
histone demethylation activity appears to be context dependent, as other groups have
reported reduced activity KDM3A in hypoxia [237]. Furthermore, many JmjC histone
demethylases are HIF target genes that are upregulated in hypoxia (reviewed in [215]),
this is thought in part to be a compensatory mechanism to counteract reduced demethylase
activity, acting as a hypoxia feedback loop similar to what is seen with transcriptional
upregulation of PHD2/3 by HIF. Thus, there is complex crosstalk between histone methy-
lation, gene expression and hypoxia, mediated in part by JmjC demethylases. However,
further characterisation of the oxygen sensitives of JmjC demethylases is needed.
3.2. TET Mediated DNA Demethylation Functions in Hypoxia
TETs, of which there are three variants—Ten Eleven Ten translocation Methylcytosine
Dioxygenase 1 (TET1), TET2 and TET3—are 2-ODGs that function as hydroxylases, mediat-
ing mammalian DNA demethylation through catalysing the oxidation of 5-methylcytosine
(5mc) to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine
(5caC). These TET oxidised derivatives of 5mc can be demethylated by mechanisms of
active and passive demethylation (reviewed in [238]). DNA methylation can repress gene
transcription, consequently tumour hypoxia results in aberrant DNA methylation pro-
files promoting tumour suppressor gene silencing (hypermethylation) [239] and oncogene
activation (hypomethylation) [240]. Recently, using in vitro biochemical binding assays,
in vivo studies on HIF binding and DNA methylation status in human cancer cell lines,
and in silico structural modelling, D’Anna and colleagues find that DNA methylation at
HREs impairs HIF binding, and HRE DNA methylation status is a key factor in determin-
ing cell type specific transcriptional responses to hypoxia [241]. There is heterogeneity
regarding the effects of hypoxia, both in cell models and in tumours, on global DNA
methylation levels and TET activity (reviewed in [203,242]). As such, whether TETs are
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impaired or functionally active in hypoxia, and the consequences this has for gene transcrip-
tion appear highly context dependent. Researchers have shown TET activity in hypoxia,
and HIF-dependent TET upregulation and coactivator functions have been demonstrated at
hypoxia-inducible genes (reviewed in [203,242]). TET activity in low oxygen environments
is supported by in vitro oxygen affinities of TET1 and TET2 (Table 1 and Supplementary
Table S1), as well as the known roles of TETs in the bone marrow and during development
where oxygen tensions are low [243,244]. Conversely, Thienpont et al. showed that severe
hypoxia (0.5% oxygen) in human and murine cells and tumour hypoxia in multiple human
tumours causes DNA hypermethylation at gene promoters correlating with gene silencing
at a subset of hypoxia repressed genes and gene silencing linked to hypoxia associated
tumour progression. DNA hypermethylation was attributed to oxygen dependent reduc-
tion in TET1 and TET2 activity in hypoxia, with a 50% reduction in activity observed at
0.3% oxygen for TET1 and 0.5% for TET2 in vitro. Thus, TET1 and TET2 may be charac-
terised as tumour oxygen sensors, and depending on the context of oxygen deprivation,
may remain active in hypoxia environments or display inhibition. However, more work
is needed to establish the oxygen dependence of TET activity in cells and in vivo and the
physiological contexts in which TETs can sense changes in oxygen availability, as well as
the consequences this has for DNA methylation, gene transcription and cellular responses.
Indeed, the seemingly contradictory roles for TETs in hypoxia from studies to date may be
dependent on the different cell models used and timing/severity of hypoxic stimulus.
While there is growing evidence for a dynamic role of chromatin/epigenetics in sens-
ing and responding to hypoxia to facilitate transcriptional changes, via HIF-dependent and
-independent mechanisms, efforts to elucidate molecular mechanisms underpinning such
changes and the extent to which chromatin/epigenetic changes are required for coordinat-
ing hypoxia/HIF transcriptional effects are ongoing. The discoveries of oxygen sensing
by TETs and JmjC demethylases provide an exciting link between oxygen availability and
chromatin regulation, and future work on oxygen sensing by chromatin will be essential
for better understanding hypoxia driven processes.
4. Effects of Hypoxia on Protein Levels
Protein levels and function are key aspects to achieve the appropriate hypoxia re-
sponse. Although transcription is important, mechanisms controlling protein levels and
function supersede any changes in transcriptional output. In hypoxia, mechanisms exist
that control translation, but also post-translation aspects of protein function.
4.1. Translation Is Globally Repressed in Response to Hypoxia
In addition to the regulation of gene transcription in hypoxia, gene expression is also
controlled through regulation of translation (Figure 4). The cellular response to hypoxia
includes a reduction in the energy expenditure of the cell due to limited ATP production
through oxidative phosphorylation. This adaptation results in a reversible global decrease
in energy-expensive protein synthesis (reviewed in [2]). This inhibition of translation is a
highly regulated response to low oxygen levels preceding ATP depletion (reviewed in [2]).
Global inhibition of protein expression is largely regulated at the point of translation
initiation through two pathways. Firstly, Mechanistic Target of Rapamycin Kinase (mTOR)
is inhibited by DNA Damage Inducible Transcript 4 (DDIT4) (a HIF target gene). DDIT4-
dependent release of TSC Complex Subunit 2 (TSC2) from 14-3-3 binding proteins leads to
mTOR inhibition. This allows the formation of an active TSC1-TSC2 dimer that inhibits
the phosphorylation of Ribosomal Protein S6 Kinase B1 (RPS6KB1) by the mTOR pro-
tein complex, which in turn inhibits the phosphorylation of Ribosomal Protein S6 (RPS6),
part of the 40S ribosomal subunit required for initiation [245]. mTOR inhibition also causes
hypophosphorylation of Eukaryotic Translation Initiation Factor (eIF) 4E Binding Protein
1 (eIF4EBP1), allowing the sequestering of eIF4E and decrease of 5’cap-dependent initi-
ation [246,247]. Secondly, PKR-like Endoplasmic Reticulum Kinase (PERK) (gene name
EIF2AK3) is phosphorylated and activated, which subsequently phosphorylates eIF2α at
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S51, causing effective inactivation [248]. Phospho-eIF2α prevents binding with eIF2B for
exchange of GDP for GTP, therefore remaining in an inactive state and preventing subse-
quent rounds of translation from the mRNA [249]. eIF2α normally recruits the initiator
aminoacylated tRNA to the 40S ribosome, thus limiting global initiation of translation. This
second mechanism is independent of HIF and as of yet has not been linked to any 2-OGD.
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Figure 4. Hypoxia induces a global inhibition of protein translation. Global translation is mostly
inhibited at initiation through mTOR inhibition of eIF4 and PERK inhibition of eIF2α, subsequently
decreasing cap-dependent translation of mRNA. mTOR is inhibited through hypoxia-induced DDIT4-
dependent release of TSC2 from 14-3-3 binding proteins, resulting in the inhibition of mTOR by
TSC1/2 dimer. Elongation is also regulated through mTOR, as well as AMPK through its inhibition of
RPS6KB1, wherein hypoxia eEF2K is not inhibited, which allows its phosphorylation and inhibition
of eEF2. PHD2 can also hydroxylate eEF2K, which in norm xia causes its disassociation from
calmodulin, decreasing its autophosphorylation. Te mination is regul ted by JMJD4-medi ed
hydroxylation of eRF1, which is required for termination. Selective translation of genes in hypoxia is
regulated by UTR sequences, such as IRES and uORFs, which allow increased translation specifically
in hypoxia. RNA binding proteins can bind to various parts of the mRNA and result in different
regulatory outcomes. The ribosome can also be hydroxylated by RIOX1 and RIOX2, though it is not
yet clear what role these modifications have.
Inhibition of translation is also regulated at the stage of polypeptide elongation.
Elongation is inhibited by phosphorylation of Eukaryotic Elongation Factor 2 (eEF2) at
T56 by eEF2 Kinase (eEF2K) [250]. This process has been shown to be dependent on
mTOR and 5′-AMP-activated protein kinase catalytic subunit alpha-1 (AMPK) (gene name
PRKAA1) [251,252]. Interestingly, eEF2 kinase (eEF2K) is also regulated by hydroxylation
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by PHD2 at P98 in an oxygen-dependent manner [253]. In hypoxia, when PHD2 inhibited,
eEF2K activity is induced.
In addition to PHD2 dependent hydroxylation, there are several other hydroxylation
reactions involved in the regulation of translation, catalysed by other 2-OGDs. Hydroxyla-
tion is important for the biosynthesis of tRNAPhe with position 37 requiring a hypermodi-
fied nucleoside Wybutosine (yW) that can be hydroxylated to form hydroxywybutosine
(OHyW) by the JmjC hydroxylase, TRNA-YW Synthesizing Protein 5 (TYW5), which main-
tains translational fidelity. It is currently unknown whether TYW5 is responsive to the
level of oxygen, but its transcription is decreased in hypoxia, [254] linking hypoxia to a
decreased accuracy of translation, which globally decreases the successful translation of
proteins [255].
The rate and accuracy of translation are positively regulated by hydroxylation of
the central translation machinery. JmjC hydroxylases Ribosomal Oxygenase 2 (RIOX2)
and RIOX1 hydroxylate histidyl residues in ribosomal proteins, with RIOX2 and RIOX1
hydroxylating Ribosomal Protein L (RPL) 27a (RPL27A) and (RPL8), respectively. The hy-
droxylation occurs at residues close to the peptidyl transfer centre, thereby increasing
translation efficiency [256]. RIOX1 and RIOX2 transcription is reduced in hypoxia [254,256].
Furthermore, RPL8 hydroxylation is also reduced in hypoxia [256]. However, it is not yet
known whether these enzymes are inhibited by low oxygen levels, or lower hydroxylation
is solely due to lower transcription. Additionally, hydroxylation of 40S Ribosomal Protein
S23 (RPS23) by the 2-OGD, 2-Oxoglutarate and Iron Dependent Oxygenase Domain Con-
taining 1 (OGFOD1), is required for efficient translation [257]. OGFOD1 transcription is also
decreased in hypoxia, but the enzyme remains mostly active, even in acute hypoxia [258],
suggesting this mechanism is not through direct 2-OGD oxygen sensing.
Efficient decoding of the mRNA during translation requires the JmjC hydroxylase,
AlkB Homolog 8, TRNA Methyltransferase, ALKBH8, which hydroxylates tRNA at the
wobble position [259,260]. This 2-OGD has yet to be linked to hypoxia, though it would be
interesting to investigate its oxygen sensitivity. Finally, lysyl hydroxylation of eukaryotic
release factor 1 (eRF1) by the JmjC hydroxylase Jumonji Domain Containing 4 (JMJD4) is
required for proper termination of translation [261], although its activity is not significantly
inhibited in hypoxia.
4.2. Utilising Proteomics for the Identification of Non-Histone Protein PTMs
Proteomics approaches have revealed hypoxia induces changes to many post transla-
tional modifications (PTMs) on non-histone proteins, such as proline hydroxylation [262,263]
(regulating protein levels and interactions), phosphorylation [264,265], SUMOylation [266],
acetylation [267], glycosylation [268], nitration [269] and nitrosylation [270], all of which
regulate protein functions in different ways.
As one of the most widely studied PTMs, phosphorylation of some transcriptional fac-
tors and regulators has been found to be changed under various hypoxic conditions, includ-
ing CAMP Responsive Element Binding Protein 1 (CREB1), NFKB Inhibitor Alpha (NFK-
BIA), a regulator of NF-κB, and HIF (reviewed in [271]). More recently, through the analysis
of phospho-proteomics in renal clear cell carcinoma cells under a VHL-independent hy-
poxic response, up-regulation of known biomarkers of RCC and signalling adaptor were
found. Meanwhile, such hypoxic responses decreased the phosphorylation on intracel-
lular Carbonic Anhydrase 2 (CA2), which might be an unusual way to control the CA2
expression and enhance the activity of the NF-κB pathway, resulting in loss of VHL [264].
In recent years, non-HIF targets have been identified to be hydroxylated on prolines
by PHDs (reviewed in [15]), resulting in their degradation and/or changes to downstream
activity including Centrosomal Protein 192 (CEP192) [272], Forkhead Box O3 (FOXO3) [273]
and Adenylosuccinate Lyase (ADSL) [274] by PHD1, Actin Beta (ACTB) by PHD3 [275],
and AKT Serine/Threonine Kinase 1 (AKT1) [93], TANK Binding Kinase 1 (TBK1) [276] and
Scm-like with Four Malignant Brain Tumour Domains 1 (SFMBT1) [277] by PHD2 [278].
Despite these exciting studies, a recent study investigating around 20 of the reported
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non-HIF substrates, failed to detect any hydroxylation in vitro [279]. This adds to the
complexity of identifying novel PHD substrates. Interestingly, a new study indicated
that prolyl-hydroxylation could be crucial for GMGC kinase activation [280]. This could
imply an intricate interplay between these two types of PTMs, suggesting yet another role
for oxygen-dependent signalling in the cell. Thus, unbiased proteomic studies on novel
PTMs sites [262,281], system-wide analysis of PHDs substrates other than HIF-α [263] and
crosstalk of PTMs on PHDs targets in response to hypoxia are now emerging.
5. Other Potential Roles of 2-OGDs in the Hypoxia Response
Further to known and potential oxygen sensing roles of JmjC 2-ODGs (JmjC demethy-
lases and hydroxylases) in the regulation of chromatin and translation discussed ear-
lier, there are other functions of JmjC 2-ODGs that may influence the hypoxia response
(Figure 5). One of the most prominent of such enzymes is the JmjC 2-OGD, JMJD6, Arginine
Demethylase and Lysine Hydroxylase, which has unique activities as both an arginine
demethylase (acting on mono- and symmetric/asymmetric di-methylated arginines) and
lysine hydroxylase [282,283]. JMJD6 expression is increased in hypoxic conditions in the
placenta and can downregulate HIF-1α [284], though it has been found to operate in
diverse pathways. JMJD6 can promote the formation of stress granules through demethyla-
tion of Arg-435, Arg-447 and Arg-460 of G3BP Stress Granule Assembly Factor 1 G3BP1,
and subsequent de-repression of the protein, resulting in the cytoplasmic sequestering of
stalled mRNA-ribosome complexes to reversibly prevent mRNA degradation [285,286].
This would allow a fast re-start of protein synthesis when oxygen homeostasis is restored.
JMJD6 also regulates mRNA splicing through hydroxylating the splicing regulatory (SR)
proteins LUC7 Like 2, Pre-MRNA Splicing Factor (LUC7L2) on Lys-269, U2 Small Nuclear
RNA Auxiliary Factor 65 (U2AF65) on Lys-15 and Lys-276 [287], and multiple fragments
of Serine and Arginine Rich Splicing Factor 11 (SRSF11) between residue 271 to 372 [283].
The SR proteins are involved in exon definition and alternative splicing, with SRSF11
hydroxylation resulting in skipping of most 5’ exon, and hydroxylation of U2AF65 possibly
enacting pre-mRNA looping in order to present to the splicing machinery different cis
splice enhancer or silencer sequences [288]. However, this only occurs for selected mRNAs
and is not a global effect [288]. Nevertheless, this mechanism would allow selection of
alternate splice variants as a response to hypoxia. JMJD6 can also interact with both Bro-
modomain Containing 4 (BRD4) and the positive Transcription Factor Elongation Factor b
(P-TEFb) complex [289], eventually resulting in the release of paused DNA polymerase II
and resumption of mRNA synthesis at specifically regulated genes [288]. This implies that
hypoxia could use this mechanism to stall transcription of genes that are not required for
the stress response to hypoxia and would allow a re-start of gene expression when oxy-
gen levels are restored. JMJD6 hydroxylates p53 on Lys382, repressing its transcriptional
activity [290]. JMJD6 also auto-hydroxylates itself on the N-terminus and this is required
for homo-oligomerisation [291]. The function of the homomultimer of JMJD6 is unknown,
but speculated to play a role as a scaffolding protein in the nucleus [292].
Another JmjC hydroxylase, KDM8, can hydroxylate arginine residues in both RCC1
Domain Containing 1 (RCCD1) and RPS6 [293]. KDM8 also has amine- and endo-peptidase
activity with specificity towards histone H3 monomethyl-lysine residues, especially of
the histone variant H3F3A [294], and arginine methylated histone tails [295,296]. It had
previously been reported that KDM8 can demethylate H3K36me2 [297], though consider-
ing its arginine demethylation is achieved through trimming of the histone tail, this may
be the mechanism of observed decreases in lysine methylation. Although not necessarily
dependent on its hydroxylation activity, KDM8 is required for cell proliferation and chro-
mosomal stability [298], and can negatively regulate p53, affecting gene expression and
control cell cycle and proliferation [299,300]. Recently, a biochemical function has been
assigned to JMJD7 as a lysyl hydroxylase, which targets Developmentally Regulated GTP
Binding Protein 1 (DRG1) and DRG2 that are part of the Translation Factor (TRAFAC) fam-
ily of GTPases, and could affect their binding with messenger, or ribosomal RNA, though
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this requires further investigation [301]. Similar to KDM8, JMJD7 also possesses endo-
and amine-peptidase activity, preferentially cleaving mono- and di-methylated arginine
residues of H2, H3, and H4 [295,296].
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able to promote the formation of stress granules, which reversibly pauses transcript translation
through demethylation of G3BP1. JMJD6 can hydroxylate splicing regulatory (SR) proteins, resulting
in differential splicing or exon choice, such as skipping the first exon with the hydroxylation of
SRSF11. JMJD6 can also hydroxylate p53 repressing its activity. KDM8 is an arginine hydroxylase
that can target RCCD1 for chromatin condensation, and RPS6, which affects translation. JMJD7 is
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Several JmjC demethylases have been found to have additional, non-histone substrates.
For example, KDM2A represses NF-κB activity via demethylation of RELA, providing a
possible li k t hypoxia and inflamm ti n crosstalk. [302]. KDM3A was rece tly found to
function as a olecular oxygen sensor, with its demethylation of K224me1 on peroxisome
proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) (which facilitates its
activity) impaired under low oxygen conditions [237]. PGC-1α is a transcriptional coacti-
vator promoting mitochondrial biogenesis and oxidative metabolism, the aforementioned
work neatly links mitochondrial function to the hypoxia response via the oxygen sens-
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ing function of KDM3A controlling PGC-1α activity, further highlighting the importance
of JmjC 2-OGDs in the hypoxia response. KDM3A can also demethylate K372me1 of
p53, which decreases its association with chromatin and represses its proapoptotic activ-
ity [303]. KDM3B, in addition to its substrate H3K9me2, can also demethylate mono- or
di-methylated arginine residues, H4R3me2 [127]. It is more than likely that other JmjC
demethylases interact and directly demethylate additional transcription factors which may
coordinate transcriptional responses to hypoxia. However, unbiased analysis is required to
fully assess this aspect of hypoxia-induced gene regulation. The KDM4 family of demethy-
lases appears to have higher activity against trimethylated non-histone targets than its
canonical substrates, H3K9me2 and H3K36me3 [304]. These substrates include widely inter-
spaced zinc finger motifs protein (WIZ), chromodomain Y-like protein (CDYL1), Cockayne
syndrome group B protein (CSB, four peptides) and Histone-lysine N-methyltransferase
(EHMT2). These substrates of KDM4 family are all members of transcription repression
complexes, suggesting an additional role of transcriptional regulation by these demethy-
lases. Using in vitro assays, KDM3A, KDM4E, KDM5C, and KDM6B have been shown
to possess arginine demethylase activity, in addition to their lysine demethylase activity
on peptide substrates [305]. Non-specific hydroxylase activities are not unusual for JmjC
enzymes, so any such reported activity should demonstrate specificity and biological rele-
vance, though it is possible that it will emerge that many lysine demethylases also possess
relevant arginine demethylase activity.
Finally, a potentially new and exciting mechanism involves an epigenetic mark in
RNA, methylation of 6 adenosine (m6A). mRNA m6A modification at the 5’UTR can
recruit m6A binding proteins such as YTH N6-Methyladenosine RNA Binding Protein 2
(YTHDF2) in heat shock stress, which upregulates translation through binding eIF3 and
the 40S subunit [306], and such a mechanism may prove true in other stress responses,
such as hypoxia. The RNA demethylating enzymes FTO Alpha-Ketoglutarate Dependent
Dioxygenase (FTO) and AlkB Homolog 5, RNA Demethylase (ALKBH5), are 2-OGDs, and
although their ability to sense oxygen has yet to be investigated, their inhibition in hypoxia
could result in an increase in global RNA methylation, which could regulate translation
and RNA fate in hypoxia.
6. Relevance to Human Biology and Health
Although we currently do not know the importance of all of the 2-OGDs present in the
genome, several of the key players in the hypoxia response have important functions and
relevance to human biology and health. This is exemplified by the phenotypes observed in
null mice, or by the presence of disease associated mutations in humans.
6.1. PHD/HIF/VHL Axis
Given the cellular functions mentioned above, it is no surprise that genetic mutations
of most dioxygenases and HIFs have been implicated with human diseases. Mutations
in HIF-2α and PHD2 have been found in patients with vascular pathologies, such as
erythrocytosis, polycythemia, and pheochromocytoma (Table 2). As HIF mediates hypoxia
adaptation responses, including the regulation of erythropoiesis and vasculogenesis, it is
not surprising that mutations within the PHD/HIF/VHL axis are associated with vascular
pathologies. The crucial role of HIFs in vascular pathologies is strongly demonstrated
by genetic studies of mice, as highlighted in Supplementary Table S2. Knockout mice
of HIF-1α or HIF-2α are embryonic lethal with vascular defects (Table 2, Supplementary
Table S2), whereas the deletion of PHD2 that activates HIF signalling results in embryonic
lethality in mice due to placental and heart defects (Table 2, Supplementary Table S2). VHL
mutations also result in highly vascularized tumours, including pheochromocytomas, renal
cell cancer carcinoma, retinal and central nervous system hemangioblastomas (Table 2).
Hundreds of VHL mutations have been identified in VHL syndrome patients (listed in the
Human Gene Mutation Database [307]). The homozygous VHL mutation R200W, which
prevents efficient HIF-α degradation in normoxia, is found in all individuals with Chuvash
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Polycythemia (CP) [308]. CP is characterized by congenital erythrocytosis, and patients
have been associated with pulmonary hypertension, thrombosis, vertebral hemangiomas,
cerebral vascular events and other vascular abnormalities [309,310], displaying the role of
VHL in HIF-dependent regulation of vasculogenesis and erythropoiesis.
6.2. 2-OGDs—Hydroxylases
Similar to PHDs, prolyl-4-hydroxylases P4HA1 and P4HA2 are hypoxia-inducible,
but P4HA1/2 prolyl hydroxylation is required for different processes, that is collagen
fiber formation. Consistent with their roles in collagen synthesis, P4HA1 and P4HA2
mutations are found in patients with collagen-related extracellular matrix disorders (Table
2; Supplementary Table S2). Furthermore, homozygous deletion of P4HA1 is embryonic
lethal with base membrane rupture due to defective collagen IV assembly (Table 2). PAHX
is another hydroxylase, but of phytanoyl-CoA; essential for breaking down phytanic
fatty acid. Mutations in PAHX is well associated with Refsum disease, a rare inherited
neurological disorder caused by neurotoxic phytanic acid as these mutations result in an
enzymatically inactive protein, thus leading to phytanic acid accumulation.
The roles of TET1–3 in development are demonstrated in knockout mouse models
(reviewed in [311]). TET1-null mice present several defects but these depend on the mode
of genetic deletion. TET3 deletion results in neonatal lethality, highlighting TET3 role in
development. TET3 mutations have been found in patients with intellectual disability
and/or delayed global development (Table 2; Supplementary Table S2). Although somatic
alterations of TET2 have been found in several cancers, these mutations are majorly associ-
ated with myelodysplastic syndromes (Table 2; Supplementary Table S2). In addition to the
listed mutations in Supplementary Table S2, a study reported TET2 somatic mutations in
46 patients with myelodysplastic syndromes, myeloproliferative disorder, secondary acute
myeloid leukemia, or chronic myelomonocytic leukemia [312]. Most of these mutations are
predicted to lead to partial or total loss of function due to protein truncation.
6.3. 2-OGDs—JmjC Demethylases
Many of the JmjC demethylase genes have been associated with human diseases.
In particular, several of them are mutated in patients with neurodevelopmental disorders,
midline defects and cancers (Table 2; Supplementary Table S2). Although KDM3A is
found to be mutated in infertile males [125], its role in infertility is not clear. Mutations
in KDM3B are frequently implicated with intellectual disability, but also found in cancers
including myeloid leukemias (Table 2). Similarly, JMJD1C mutations have been identified
in individuals with autism spectrum disorder and intellectual disability. JMJD1C is also as-
sociated with congenital heart disease manifestation in 22q11.2 deletion syndrome patients.
Amongst KDM4s, there are only two reports—single nucleotide substitutions of KDM4C in
upper aerodigestive tract cancer and age of menarche. Mutations of KDM5B, KDM5C and
KDM6B have been associated with neurodevelopment and a global developmental delay
(Table 2; Supplementary Table S2). In particular, KDM5C is well recognised as an X-linked
intellectual disability gene that is highly expressed in neural tissue. Mutations in PHD
Finger Protein 8 (PHF8) are also associated with X-linked mental retardation and often
accompanied by cleft lip/palate or autism. The phenotypes of KDM5C or PHF8 mutations
in humans are reflected by the deletion of these genes in mice (Table 2). On the other hand,
KDM6A mutations are frequently found in individuals with Kabuki syndrome (KS), a ge-
netic disease with developmental delay and congenital anomalies, (Table 2) highlighting the
role of KDM6A in development. In addition to mutations listed in Supplementary Table S2,
others have reported gross deletions, gross duplications, or chromosomal rearrangement in
patients with KS or KS-like clinical manifestations [176,178,313–315]. However, whether the
phenotypes observed are due to loss of demethylase activity solely is currently unknown.
Oxygen regulation is pivotal for embryogenesis as most developmental processes dur-
ing early embryo development occurs in a hypoxic environment [316]. Given the fact that
2-OGDs sense and respond to oxygen levels, it is not surprising that mutations affecting the
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activity of several of these enzymes are detrimental to embryo development, contributing
to neonatal defects. The hypoxic environment is also a common feature of tumours due to
aberrant vascularisation and an inadequate supply of blood [317]. Mutations or deletions of
some of these 2-OGDs are implicated in cancers. The molecular mechanisms through which
2-OGDs promote cancers is not completely understood. However, altered metabolism in
cancer has been linked to alteration of 2-OGDs function (reviewed in [318]). 2-OGDs can
be inhibited by metabolites that are accumulated in tumours, including succinate, fumarate
and D/L-2-hydroxyglutarate [318,319]. It is thus very likely that the phenotypes observed
in deletions and mutations are the result of both alteration of the hypoxia response and
changes in metabolism. Overall, the presence and connections of HIFs or dioxygenase
mutations in human disorders and the knockout studies demonstrate the essential roles of
these genes.
7. Conclusions and Future Perspectives
As our understanding of the cellular response to hypoxia advances, new aspects
continue to unravel. The role of oxygen has surfaced as far broader than just an acceptor
molecule in oxidative phosphorylation in the mitochondria. Through acting as a co-factor
for diverse and functionally important enzymes, oxygen is mechanistically identified as a
potent signalling molecule in cells. The emerging focus of the field includes new aspects
of chromatin regulation, RNA biology and broad regulation of protein post-translational
modifications directly controlled by oxygen levels. This advanced understanding in con-
junction with development of novel therapeutic chemicals targeting dioxygenases should
provide not only exciting new biological insights, but also better treatments for patients
suffering from a range of diseases. One area of technological advancement that will greatly
progress the field is the adaptation of novel and unbiased quantitative techniques for
measuring chromatin structure, transcriptional output, proteomic changes and cellular be-
havior. These approaches may provide resolution to some of the persisting major questions
pertaining mechanisms controlling gene expression in response to hypoxia.
Supplementary Materials: The following are available online at https://www.mdpi.com/2072-6
694/13/2/350/s1, Supplementary Table S1: 2-OGDs reported affinities for oxygen from in vitro
assays; Supplementary Table S2: Known mutations in the hypoxia signalling system in humans, and
Supplementary Table references.
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